Dataset Information

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

ABSTRACT: There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania donovani both in vitro and in vivo. Twice-daily oral dosing of delamanid at 30 mg kg(-1) for 5 days resulted in sterile cures in a mouse model of VL. Treatment with lower doses revealed a U-shaped (hormetic) dose-response curve with greater parasite suppression at 1 mg kg(-1) than at 3 mg kg(-1) (5 or 10 day dosing). Dosing delamanid for 10 days confirmed the hormetic dose-response and improved the efficacy at all doses investigated. Mechanistic studies reveal that delamanid is rapidly metabolised by parasites via an enzyme, distinct from the nitroreductase that activates fexinidazole. Delamanid has the potential to be repurposed as a much-needed oral therapy for VL.

SUBMITTER: Patterson S

PROVIDER: S-EPMC4878867 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Patterson Stephen S Wyllie Susan S Norval Suzanne S Stojanovski Laste L Simeons Frederick Rc FR Auer Jennifer L JL Osuna-Cabello Maria M Read Kevin D KD Fairlamb Alan H AH

eLife 20160524

There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania donovani both in vitro and in vivo. Twice-daily oral dosing of delamanid at 30 mg kg(-1) for 5 days resulted in sterile cures in a mouse model of VL. Treatment with lower doses revealed a U-shaped (hormetic) dose-response curve with greater parasite ...[more]

PMID: 27215734

Similar Datasets

Project description:BACKGROUND: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the VL elimination program. METHODOLOGY AND PRINCIPAL FINDINGS: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L. donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL susceptibility of post-treatment isolates from cured VL cases (n?=?13, mean IC(50)±SD?=?2.43±1.44 µM), was comparable (p>0.05) whereas that from relapses (n?=?3, mean IC(50)?=?4.72±1.99 µM) was significantly higher (p?=?0.04) to that of the pre-treatment group (n?=?6, mean IC(50)?=?1.86±0.75 µM). In PKDL, post-treatment isolates (n?=?3, mean IC(50)?=?16.13±2.64 µM) exhibited significantly lower susceptibility (p?=?0.03) than pre-treatment isolates (n?=?5, mean IC(50)?=?8.63±0.94 µM). Overall, PKDL isolates (n?=?8, mean IC(50)?=?11.45±4.19 µM) exhibited significantly higher tolerance (p<0.0001) to MIL than VL isolates (n?=?22, mean IC(50)?=?2.58±1.58 µM). Point mutations in the miltefosine transporter (LdMT) and its beta subunit (LdRos3) genes previously reported in parasites with experimentally induced MIL resistance were not present in the clinical isolates. Further, the mRNA expression profile of these genes was comparable in the pre- and post-treatment isolates. Parasite isolates from VL and PKDL cases were uniformly susceptible to PMM with respective mean IC(50)?=?7.05±2.24 µM and 6.18±1.51 µM. CONCLUSION: The in vitro susceptibility of VL isolates remained unchanged at the end of MIL treatment; however, isolates from relapsed VL and PKDL cases had lower susceptibility than the pre-treatment isolates. PKDL isolates were more tolerant towards MIL in comparison with VL isolates. All parasite isolates were uniformly susceptible to PMM. Mutations in the LdMT and LdRos3 genes as well as changes in the expression of these genes previously correlated with experimental resistance to MIL could not be verified for the field isolates.

Dataset Information

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Publications

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets